Become a digitalPLUS subscriber. 99¢ for 4 weeks.

Drug cuts breast cancer risk for some post-menopausal women

Exemestane, sold as Aromasin, can reduce the risk of tumors in high- and moderate-risk post-menopausal women by 65% over a three-year period, researchers reported June 4 in the New England Journal of Medicine. Aromasin, a drug already used to treat breast cancer, does not appear to have the... Ben Edwards / Getty Images
Loading